CG Oncology, Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
CGON$72.64-2.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating Activities | ||
| Net loss | $(34,452) | $(16,934) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 24 | 4 |
| Stock-based compensation expense | 5,151 | 1,517 |
| Accretion of discount on short-term investments | (279) | (2,199) |
| Non-cash interest income | (176) | — |
| Non-cash lease expense | (14) | (3) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (982) | (5,654) |
| Accounts receivable - other | 436 | — |
| Other assets | (35) | (33) |
| Accounts payable | 214 | 1,417 |
| Accrued expenses and other current liabilities | 836 | (4,127) |
| Net cash used in operating activities | (29,277) | (26,012) |
| Investing Activities | ||
| Proceeds from sales and maturities of short-term investments | 200,139 | 145,865 |
| Purchases of short-term investments | (361,892) | (453,297) |
| Issuance of note receivable | (25,000) | — |
| Purchases of property and equipment | (16) | (12) |
| Net cash used in investing activities | (186,769) | (307,444) |
| Financing Activities | ||
| Proceeds from initial public offering, net of issuance costs | — | 406,410 |
| Payments of success fee or long-term debt | — | (365) |
| Proceeds from exercise of common stock options and issuance of common stock under the employee stock purchase plan | 682 | — |
| Deferred offering costs | (232) | (3,387) |
| Net cash provided by financing activities | 450 | 402,658 |
| Net (decrease) increase in cash and cash equivalents | (215,596) | 69,202 |
| Cash and cash equivalents at beginning of period | 257,068 | 8,266 |
| Cash and cash equivalents at end of period | $41,472 | $77,468 |
| Supplemental Schedule of Non-cash Investing and Financing Activities: | ||
| Reclassification of 38,413,909 redeemable convertible preferred stock to 38,413,909 shares of common stock | $— | $307,890 |
| Conversion of deferred offering costs | $— | $6,845 |
| Deferred offering costs, unpaid and accrued | $215 | $— |
| Operating lease right-of-use asset obtained in exchange for lease liabilities | $859 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.